## Maximilian Christopeit

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9396501/publications.pdf

Version: 2024-02-01

47 1,156 18 32 papers citations h-index g-index

51 51 51 1879
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation. Haematologica, 2022, 107, 857-867.	1.7	32
2	Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis. Bone Marrow Transplantation, 2022, 57, 510-512.	1.3	6
3	Post-transplant MFC-MRD status on day $\pm 100$ predicts outcomes for refractory AML patients Transplantation and Cellular Therapy, 2022, , .	0.6	3
4	Detection of human herpes virus 6 DNA and chromosomal integration after allogeneic hematopoietic stem cell transplantation: a retrospective single center analysis. Transplant Infectious Disease, 2022, , .	0.7	5
5	Scabies crustosa in a recipient of an allogeneic stem cell transplantation. Infection, 2021, 49, 375-376.	2.3	2
6	Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. Transplantation and Cellular Therapy, 2021, 27, 95.e1-95.e4.	0.6	12
7	Role of preâ€transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML. European Journal of Haematology, 2021, 106, 606-615.	1.1	12
8	Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Annals of Hematology, 2021, 100, 321-336.	0.8	34
9	Viral Dynamics of SARS-CoV-2 in Critically Ill Allogeneic Hematopoietic Stem Cell Transplant Recipients and Immunocompetent Patients with COVID-19. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 242-245.	2.5	12
10	Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection. Bone Marrow Transplantation, 2021, $56$ , $1478-1481$ .	1.3	9
11	Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza. Scientific Reports, 2021, 11, 5803.	1.6	40
12	TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2021, 12, 630429.	2.2	19
13	A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. Blood Advances, 2021, 5, 1760-1769.	2.5	22
14	Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). Annals of Hematology, 2021, 100, 1603-1620.	0.8	39
15	Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19. IScience, 2021, 24, 102752.	1.9	9
16	"Per aspera ad astra"Â… die Facharztreife. Onkologe, 2021, 27, 2-4.	0.7	0
17	Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT. Journal of Neurology, 2020, 267, 430-439.	1.8	13
18	Incidence and Outcome of Late Relapse after Allogeneic Stem Cell Transplantation for Myelofibrosis. Biology of Blood and Marrow Transplantation, 2020, 26, 2279-2284.	2.0	4

#	Article	IF	Citations
19	Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2020, 26, 2047-2052.	2.0	6
20	Major central nervous system complications after allogeneic stem cell transplantation: A large retrospective study on 888 consecutive adult patients. European Journal of Haematology, 2020, 105, 722-730.	1.1	5
21	Second allogeneic stem cell transplantation for relapse after allografting in multiple myeloma using CD 34+ selected donor cells without immunosuppression. Bone Marrow Transplantation, 2020, 55, 1817-1820.	1.3	1
22	Acute Myeloid Leukemia Stem Cells: The Challenges of Phenotypic Heterogeneity. Cancers, 2020, 12, 3742.	1.7	32
23	Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis. Cancers, 2020, 12, 3098.	1.7	10
24	Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1. Science Translational Medicine, 2020, 12, .	5.8	17
25	Monocenter study on epidemiology, outcomes, and risk factors of infections in recipients of 166 allogeneic stem cell transplantations during 1Âyear. European Journal of Haematology, 2020, 105, 126-137.	1.1	7
26	Clonal Evolution after Allogeneic Hematopoietic Stem Cell Transplantation: The Case of Myelofibrosis. Biology of Blood and Marrow Transplantation, 2020, 26, e167-e170.	2.0	0
27	Treatment of invasive fungal diseases in cancer patientsâ€"Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Mycoses, 2020, 63, 653-682.	1.8	42
28	Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level. Bone Marrow Transplantation, 2020, 55, 2286-2293.	1.3	22
29	Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years. European Journal of Haematology, 2019, 103, 370-378.	1.1	11
30	Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) Are Associated with Poorer Outcome after Single Mismatch Unrelated Donor Stem Cell Transplantation: A Study of the Cooperative Transplant Study Group (KTS) of the German Group for Bone Marrow and Stem Cell Transplantation (DAG-KBT). Transfusion Medicine and Hemotherapy, 2019, 46, 370-375.	0.7	8
31	Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, e128-e140.	2.0	40
32	Acute hepatitis as a prequel to very severe aplastic anemia. Zeitschrift Fur Gastroenterologie, 2018, 56, 51-54.	0.2	4
33	Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT. American Journal of Hematology, 2018, 93, 1532-1542.	2.0	10
34	Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 2152-2156.	2.0	65
35	Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. European Journal of Haematology, 2018, 101, 305-317.	1.1	39
36	Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2018, 24, 2558-2567.	2.0	43

#	Article	IF	CITATIONS
37	Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology ( <scp>AGIHO</scp> ). Mycoses, 2018, 61, 796-813.	1.8	69
38	ABR, a novel inducer of transcription factor C/EBPα, contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemia. Oncotarget, 2017, 8, 103626-103639.	0.8	13
39	Community acquired respiratory virus infections in cancer patients—Guideline on diagnosis and management by the Infectious Diseases Working PartyÂof the German Society for haematology and Medical Oncology. European Journal of Cancer, 2016, 67, 200-212.	1.3	66
40	Correlation of somatic mutations with outcome after FLAMSAâ€busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes. European Journal of Haematology, 2016, 97, 288-296.	1.1	14
41	Ruxolitinib during Peritransplant Period for Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplantation Reduces Acute Graft-Versus-Host Disease. Blood, 2016, 128, 2242-2242.	0.6	5
42	Impact of Donor-Recipient Histocompatibility and CMV-Mismatch on Outcome of Allogeneic Stem Cell Transplantation for AML and MDS: A Retrospective Registry Study of the German Stem Cell Transplant Registry (DRST) of the German Working Group for Blood and Marrow Transplantation (DAG-KBT). Blood, 2016, 128, 2304-2304.	0.6	1
43	Relapse assessment following allogeneic SCT in patients with MDS and AML. Annals of Hematology, 2014, 93, 1097-1110.	0.8	9
44	Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). Annals of Hematology, 2014, 93, 1083-1095.	0.8	86
45	HSC commitment–associated epigenetic signature is prognostic in acute myeloid leukemia. Journal of Clinical Investigation, 2014, 124, 1158-1167.	3.9	38
46	Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change. Journal of Clinical Oncology, 2013, 31, 3259-3271.	0.8	137
47	Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse. Haematologica, 2013, 98, 518-525.	1.7	31